Bioreductively Activatable Prodrug Conjugates of Combretastatin A-1 and Combretastatin A-4 as Anticancer Agents Targeted toward Tumor-Associated Hypoxia.

A549 Cells Animals Antineoplastic Agents, Phytogenic / chemistry Breast Neoplasms / drug therapy Cell Hypoxia Colchicine / metabolism Drug Screening Assays, Antitumor Female Humans Mice Mice, Inbred BALB C NADPH-Ferrihemoprotein Reductase / chemistry Prodrugs / chemistry Stilbenes / chemistry Tubulin / drug effects

Journal

Journal of natural products
ISSN: 1520-6025
Titre abrégé: J Nat Prod
Pays: United States
ID NLM: 7906882

Informations de publication

Date de publication:
24 04 2020
Historique:
pubmed: 21 3 2020
medline: 22 6 2021
entrez: 21 3 2020
Statut: ppublish

Résumé

The natural products combretastatin A-1 (CA1) and combretastatin A-4 (CA4) function as potent inhibitors of tubulin polymerization and as selective vascular disrupting agents (VDAs) in tumors. Bioreductively activatable prodrug conjugates (BAPCs) can enhance selectivity by serving as substrates for reductase enzymes specifically in hypoxic regions of tumors. A series of CA1-BAPCs incorporating

Identifiants

DOI: 10.1021/acs.jnatprod.9b00773 PMID: 32196334 PMC: PMC7644341
pubmed: 32196334
doi: 10.1021/acs.jnatprod.9b00773
pmc: PMC7644341
mid: NIHMS1585264
doi:

Substances chimiques

Antineoplastic Agents, Phytogenic 0
Prodrugs 0
Stilbenes 0
Tubulin 0
combretastatin A-1 2222ATS339
NADPH-Ferrihemoprotein Reductase EC 1.6.2.4
fosbretabulin I5590ES2QZ
Colchicine SML2Y3J35T

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

937-954

Subventions

Organisme : NCI NIH HHS
ID : R01 CA140674
Pays : United States
Organisme : NCRR NIH HHS
ID : S10 RR024757
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA142543
Pays : United States
Organisme : CCR NIH HHS
ID : HHSN261200800001C
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261200800001E
Pays : United States

Références

Br J Radiol. 1979 Aug;52(620):650-6
pubmed: 486895
Integr Biol (Camb). 2011 Apr;3(4):375-87
pubmed: 21321746
J Pharm Pharmacol. 2003 Aug;55(8):1045-53
pubmed: 12956893
Molecules. 2014 Sep 26;19(10):15361-73
pubmed: 25264827
Experientia. 1989 Feb 15;45(2):209-11
pubmed: 2920809
Mol Pharmacol. 1988 Aug;34(2):200-8
pubmed: 3412321
Cancer Treat Rev. 2011 Feb;37(1):63-74
pubmed: 20570444
Nat Rev Clin Oncol. 2012 Dec;9(12):674-87
pubmed: 23149893
J Nat Prod. 2009 Mar 27;72(3):507-15
pubmed: 19125622
PLoS One. 2012;7(8):e43314
pubmed: 22937031
Nat Protoc. 2006;1(3):1112-6
pubmed: 17406391
J Med Chem. 1995 May 12;38(10):1666-72
pubmed: 7752190
Clin Cancer Res. 2012 Mar 1;18(5):1415-25
pubmed: 22235096
J Med Chem. 1998 May 7;41(10):1688-95
pubmed: 9572894
Br J Cancer. 2000 Feb;82(3):651-6
pubmed: 10682679
Nat Rev Cancer. 2005 Jun;5(6):423-35
pubmed: 15928673
Clin Oncol (R Coll Radiol). 2007 Aug;19(6):443-56
pubmed: 17459681
Cancer Res. 1998 Apr 1;58(7):1486-93
pubmed: 9537252
J Med Chem. 2000 Jul 13;43(14):2731-7
pubmed: 10893310
Biochem Pharmacol. 2003 Oct 1;66(7):1199-206
pubmed: 14505799
Anticancer Drug Des. 1998 Apr;13(3):183-91
pubmed: 9595032
Clin Transl Oncol. 2014 Feb;16(2):115-21
pubmed: 23979912
J Natl Cancer Inst. 1991 Jun 5;83(11):757-66
pubmed: 2041050
Cancer Res. 1976 Aug;36(8):2807-12
pubmed: 1277191
Oncol Rep. 2010 Mar;23(3):685-92
pubmed: 20127007
Cell Rep. 2014 Jul 24;8(2):402-9
pubmed: 25017065
Mol Cancer Ther. 2006 Nov;5(11):2886-94
pubmed: 17121936
J Nat Prod. 1987 Jan-Feb;50(1):119-31
pubmed: 3598594
Nat Protoc. 2009;4(9):1245-51
pubmed: 19661994
Pharmacol Ther. 2015 Sep;153:107-24
pubmed: 26073310
Biochim Biophys Acta. 1981 Jul;675(2):226-31
pubmed: 6115675
Bull Exp Biol Med. 2015 Feb;158(4):581-8
pubmed: 25705045
Anticancer Drug Des. 2000 Jun;15(3):203-16
pubmed: 11049088
Cancer Lett. 2015 Dec 1;369(1):229-41
pubmed: 26325604
Oncologist. 2007 Apr;12(4):443-50
pubmed: 17470687
Cancer Res. 1999 Apr 1;59(7):1626-34
pubmed: 10197639
Bioorg Med Chem Lett. 2017 Feb 1;27(3):636-641
pubmed: 28007448
Cancer Res. 1987 Jan 15;47(2):597-601
pubmed: 3791244
FASEB J. 2008 Jul;22(7):2445-51
pubmed: 18263704
Methods Mol Med. 2005;110:39-48
pubmed: 15901925
Cancer Res. 2004 Jan 15;64(2):736-42
pubmed: 14744792
J Med Chem. 2019 Jun 13;62(11):5594-5615
pubmed: 31059248
Cell Biochem Biophys. 2003;38(1):1-22
pubmed: 12663938
BMC Cancer. 2008 Aug 09;8:228
pubmed: 18691423
Cancer Res. 2008 Apr 1;68(7):2301-11
pubmed: 18381437
Cancer. 2004 Jun 15;100(12):2491-9
pubmed: 15197790
Anticancer Drug Des. 1995 Jun;10(4):299-309
pubmed: 7786396
J Nat Prod. 2011 Jul 22;74(7):1568-74
pubmed: 21718055
Anticancer Drug Des. 1998 Dec;13(8):981-93
pubmed: 10335271
J Nat Prod. 2010 Jun 25;73(6):1093-101
pubmed: 20496923
J Med Chem. 2008 Apr 24;51(8):2412-20
pubmed: 18257544
Bioorg Med Chem. 2006 May 1;14(9):3231-44
pubmed: 16442292
Am J Cancer Res. 2016 Sep 01;6(9):1906-1921
pubmed: 27725898
J Clin Oncol. 2000 Mar;18(6):1351-9
pubmed: 10715308
Nat Rev Cancer. 2011 Jun;11(6):393-410
pubmed: 21606941
Semin Radiat Oncol. 2004 Jul;14(3):198-206
pubmed: 15254862
Nature. 2000 Sep 14;407(6801):249-57
pubmed: 11001068
Cancer Res. 1997 May 15;57(10):1829-34
pubmed: 9157969
Angiogenesis. 2013 Jul;16(3):663-74
pubmed: 23471463
Int J Hyperthermia. 2008 Feb;24(1):57-65
pubmed: 18214769
J Nat Prod. 2008 Mar;71(3):313-20
pubmed: 18303849
Clin Ther. 2006 Nov;28(11):1779-802
pubmed: 17212999

Auteurs

Blake A Winn (BA)

Department of Chemistry and Biochemistry, Baylor University, One Bear Place #97348, Waco, Texas 76798-7348, United States.

Laxman Devkota (L)

Department of Chemistry and Biochemistry, Baylor University, One Bear Place #97348, Waco, Texas 76798-7348, United States.

Bunnarack Kuch (B)

Department of Chemistry and Biochemistry, Baylor University, One Bear Place #97348, Waco, Texas 76798-7348, United States.

Matthew T MacDonough (MT)

Department of Chemistry and Biochemistry, Baylor University, One Bear Place #97348, Waco, Texas 76798-7348, United States.

Tracy E Strecker (TE)

Department of Chemistry and Biochemistry, Baylor University, One Bear Place #97348, Waco, Texas 76798-7348, United States.

Yifan Wang (Y)

Department of Chemistry and Biochemistry, Baylor University, One Bear Place #97348, Waco, Texas 76798-7348, United States.

Zhe Shi (Z)

Department of Chemistry and Biochemistry, Baylor University, One Bear Place #97348, Waco, Texas 76798-7348, United States.

Jeni L Gerberich (JL)

Predictive Imaging Research Laboratory, Department of Radiology, The University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas 75390-9058, United States.

Deboprosad Mondal (D)

Department of Chemistry and Biochemistry, Baylor University, One Bear Place #97348, Waco, Texas 76798-7348, United States.

Alejandro J Ramirez (AJ)

Mass Spectrometry Center, Baylor University, One Bear Place #97046, Waco, Texas 76798-7046, United States.

Ernest Hamel (E)

Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick National Laboratory for Cancer Research, National Institutes of Health, Frederick, Maryland 21702, United States.

David J Chaplin (DJ)

Department of Chemistry and Biochemistry, Baylor University, One Bear Place #97348, Waco, Texas 76798-7348, United States.
Fast Biopharma Ltd., 10 Aston Park, Aston Rowant, OX49 5SW, United Kingdom.

Peter Davis (P)

Fast Biopharma Ltd., 10 Aston Park, Aston Rowant, OX49 5SW, United Kingdom.

Ralph P Mason (RP)

Predictive Imaging Research Laboratory, Department of Radiology, The University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas 75390-9058, United States.

Mary Lynn Trawick (ML)

Department of Chemistry and Biochemistry, Baylor University, One Bear Place #97348, Waco, Texas 76798-7348, United States.

Kevin G Pinney (KG)

Department of Chemistry and Biochemistry, Baylor University, One Bear Place #97348, Waco, Texas 76798-7348, United States.
ORCID: 0000-0003-1262-8631

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Cellules › Cellules épithéliales › Cellules A549 › Bioreductively Activatable Prodrug Conjugates...
questionsmedicales.fr › Eucaryotes › Animaux › Bioreductively Activatable Prodrug Conjugates...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Antinéoplasiques d'origine végétale › Bioreductively Activatable Prodrug Conjugates...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Maladies du sein › Tumeurs du sein › Bioreductively Activatable Prodrug Conjugates...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Respiration cellulaire › Hypoxie cellulaire › Bioreductively Activatable Prodrug Conjugates...
questionsmedicales.fr › Composés hétérocycliques › Alcaloïdes › Colchicine › Bioreductively Activatable Prodrug Conjugates...
questionsmedicales.fr › Techniques d'investigation › Évaluation préclinique de médicament › Tests de criblage d'agents antitumoraux › Bioreductively Activatable Prodrug Conjugates...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Bioreductively Activatable Prodrug Conjugates...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Bioreductively Activatable Prodrug Conjugates...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Lignées consanguines de souris › Souris de lignée BALB C › Bioreductively Activatable Prodrug Conjugates...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Oxidoreductases › NADH, NADPH oxidoreductases › Cytochrome reductases › NADPH-ferrihemoprotéine reductase › Bioreductively Activatable Prodrug Conjugates...
questionsmedicales.fr › Préparations pharmaceutiques › Promédicaments › Bioreductively Activatable Prodrug Conjugates...
questionsmedicales.fr › Composés chimiques organiques › Hydrocarbures › Hydrocarbures cycliques › Hydrocarbures aromatiques › Dérivés du benzène › Composés benzylidéniques › Stilbènes › Bioreductively Activatable Prodrug Conjugates...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines de tissu nerveux › Tubuline › Bioreductively Activatable Prodrug Conjugates...